CardiovascularInvestigational

Serelaxin (Relaxin-2)

Intravenous

Overview

Serelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked by disulfide bonds. It acts via the relaxin family peptide receptor 1 (RXFP1) to promote vasodilation, inhibit fibrosis, and modulate hemodynamics.

Mechanism of Action

The therapeutic rationale targets acute heart failure by improving renal perfusion and reducing vascular resistance..

Research Summary & Key Findings

The RELAX-AHF trial (Lancet, 2013) demonstrated improved dyspnea and reduced 180-day mortality in acute heart failure patients, but the subsequent RELAX-AHF-2 trial (JAMA, 2017) failed to confirm a mortality or cardiovascular event benefit. The FDA did not approve serelaxin, and further development was discontinued.

Clinical Status

Investigational

Serelaxin (Relaxin-2) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Serelaxin (Relaxin-2) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Serelaxin (Relaxin-2).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.